Baseline antiretroviral resistance and clinical outcomes in an Urban HIV clinic

AIDS Patient Care and STDs

Volumn 27, Issue 4, 2013, Pages 205-207

  Klibanov, Olga M ^a   Dolder, Christian R ^a   Assefa, Ferealem ^a   Ekwonu, Tagbo J ^b  

^a WINGATE UNIVERSITY   (United States)

^b Eastowne Family Physicians   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ANTIVIRAL RESISTANCE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOSPITAL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; OUTCOME ASSESSMENT; OUTPATIENT DEPARTMENT; PATIENT CARE; TREATMENT FAILURE;

ADULT; AMBULATORY CARE FACILITIES; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG RESISTANCE, VIRAL; FEMALE; HIV; HIV INFECTIONS; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MUTATION; NORTH CAROLINA; PREVALENCE; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; RNA-DIRECTED DNA POLYMERASE; SOCIOECONOMIC FACTORS; TREATMENT OUTCOME; URBAN POPULATION;

EID: 84876109151     PISSN: 10872914     EISSN: 15577449     Source Type: Journal    
DOI: 10.1089/apc.2013.0023     Document Type: Letter

References (12)

1. Ocfemia CB, Kim D, Ziebell R, et al. Prevalence and trends of transmitted drug resistance-associated mutations by duration of infection among persons newly diagnosed with HIV-1 infection: 5 states and 3 municipalities, US, 2006 to 2009. 19th Conference on Retroviruses and Opportunistic Infections, Poster 730. Seattle, WA, March 5-8, 2012.
2. US Department of Health and Human Services Panel on Clinical Practices for Treatment of HIV Infection. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. February 12, 2013. www.aidsinfo.nih.gov (last accessed March 5, 2013).
3. Blanchard E, Klibanov OM, Axelrod P, et al. Virologic success in an urban HIV clinic: Outcomes at 12 months in patients who were HAART na?̈ve. HIV Clin Trials 2008;9: 186-191. (Pubitemid 351892872)
4. Lucas GM, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: Risk factors for virologic failure and adverse drug reactions. Ann Intern Med 1999;131:81-87. (Pubitemid 29340558)
5. Robbins GK, Daniels B, Zheng H, et al. Predictors of antiretroviral treatment failure in an urban HIV clinic. J Acquir Immune Defic Syndr 2007;44:30-37. (Pubitemid 46052217)
6. Johnson VA, Calvez V, Gunthard HF, et al. Special Contribution:-2011 Update of the drug resistance mutations in HIV-1. Top Antivir Med 2011;19:156-164.
7. Bennett DE, Camacho RJ, Otelea D, et al. Drug resistance mutations for surveillance of transmitted HIV-1 drug resistance: 2009 update. PLoS ONE 2009;4:e4724.
8. Giordano TP, Visnegarwala F, White Jr AC, et al. Patients referred to an urban HIV clinic frequently fail to establish care: Factors predicting failure. AIDS Care 2005;17: 773-783. (Pubitemid 41113015)
9. Murphy P, Cocohoba J, Tang A, et al. Impact of HIV-specialized pharmacies on adherence and persistence with antiretroviral therapy. AIDS Patient Care STDs 2012;26:526-531.
10. Ma A, Chen DM, Chau FM, et al. Improving adherence and clinical outcomes through an HIV pharmacist's interventions. AIDS Care 2010;22:1189-1194.
11. Johnston Roberts K. Physician-patient relationships, patient satisfaction, and antiretroviral medication adherence among HIV-infected adults attending a public health clinic. AIDS Patient Care STDs 2002;16:43-50.
12. Lucas GM, Gebo KA, Chaisson RE, et al. Longitudinal assessment of the effects of drug and alcohol abuse on HIV-1 treatment outcomes in an urban clinic. AIDS 2002;16:767-774. (Pubitemid 34274467)